Sri Dalada Maligawa – 3D-Scanning and Documentation of the Temple of the Sacred Tooth Relic at Kandy, Sri Lanka

Sri Dalada Maligawa – the Temple of the Sacred Tooth Relic – is one of the most important pilgrim sites in Buddhist culture. It is the main part of the UNESCO World Heritage Site Sacred City of Kandy. Since the end of the 17th century the temple has been keeping the sacred tooth of the Buddha. Until now an accurate documentation of the temple with all its rich decorations is missing. The Temple is built in an area vulnerable to environmental factors like earthquakes or monsoon rains and was the target of terrorist attacks. To help preserving this important cultural heritage a research project was carried out. Main part of the project was a 3D-documentation of the entire temple by using Terrestrial-Laser-Scanning (TLS) and the creating of CAD-Plans. In addition to the documentation of the architecture several details were taken in high resolution by Structured-Light-Scanning (SLS). All data will be part of the digital archive of the temple and were used as a base for a general site monitoring, especially to observe cracks. Next to the mere documentation a transfer of knowledge was another aim of the project. In future most of the analysis of the scan data can be done by local specialists

INFRARED THERMAL IMAGING AS A NON-DESTRUCTIVE INVESTIGATION METHOD FOR BUILDING ARCHAEOLOGICAL PURPOSES

Abstract. The presented research approach evaluates the applicability of IRT as a non-destructive testing method for Building Archaeological scientific purposes. Within a qualitative thermographic analysis, focusing on the examination of thermal patterns and anomalies, the evidence of Building Archaeological phenomena is demonstrated. Several radiometric assessments display how hitherto unknown subsurface structures and constructive interrelations are detected and simultaneously evaluated in order to both describe the historic fabric’s quality and integrate them into the comprehensive Building Archaeological stratigraphic analysis. With IRT providing a standardised mapping of material features, structural configurations and thermal anomalies, the procedure presented enables more detailed estimations of both condition and constructive contiguity of historic fabric in a comprehensive assessment. </jats:p

Sri Dalada Maligawa – 3D-Scanning and Documentation of the Temple of the Sacred Tooth Relic at Kandy, Sri Lanka

Sri Dalada Maligawa – the Temple of the Sacred Tooth Relic – is one of the most important pilgrim sites in Buddhist culture. It is the main part of the UNESCO World Heritage Site Sacred City of Kandy. Since the end of the 17th century the temple has been keeping the sacred tooth of the Buddha. Until now an accurate documentation of the temple with all its rich decorations is missing. The Temple is built in an area vulnerable to environmental factors like earthquakes or monsoon rains and was the target of terrorist attacks. To help preserving this important cultural heritage a research project was carried out. Main part of the project was a 3D-documentation of the entire temple by using Terrestrial-Laser-Scanning (TLS) and the creating of CAD-Plans. In addition to the documentation of the architecture several details were taken in high resolution by Structured-Light-Scanning (SLS). All data will be part of the digital archive of the temple and were used as a base for a general site monitoring, especially to observe cracks. Next to the mere documentation a transfer of knowledge was another aim of the project. In future most of the analysis of the scan data can be done by local specialists

Evaluation of the Patient Medication Counseling Services in the Philippine General Hospital Using the CIPP Model

Objectives. The patient medication counseling (PMC) services at Philippine General Hospital (PGH) started 21 years ago. While several changes have been incorporated into the program, no formal evaluation has been conducted to date. The objective of this evaluation was to assess the relevance, usefulness, responsiveness, acceptability, efficiency, impact, and sustainability of the service using the context, input, process (CIPP) model of Stufflebeam.&#x0D; Methods. The study utilized a mixed-methods study design. Interviews and surveys were conducted on pharmacist-counselors, a purposive sample of doctors, nurses, and other stakeholders. A review of records from the Department of Pharmacy of UP College of Pharmacy (UPCP) and PGH, such as patient and student satisfaction surveys and monthly reports of counseled patients served from 2015 to 2019, was conducted. The results were analyzed using descriptive statistics for quantitative data and content analysis for qualitative data.&#x0D; Results. Context evaluation revealed that the establishment of PMC resulted from informal interactions with hospitalized patients due to incorrect use of prescription medicines. Correct information was envisioned to address the irresponsible use of medicines. The input evaluation revealed that only 24% (N=75) of the pharmacists are involved in PMC, which comprise only 10% of their workload. There was also a lack of comprehensive training for counseling and insufficient physical facilities. The process evaluation identified lack of time (94%) as a significant limiting factor for the involvement of pharmacists in PMC. The interns became an additional workforce for the service, but scheduling and the consistent availability of both students and faculty-preceptors were experienced. The product evaluation revealed positive perceptions among the pharmacists, faculty, and student interns. From the patient satisfaction survey records of 5,071 patients counseled, 98 to 100% expressed high service satisfaction, and 100% were likely to recommend PMC to other patients. The pharmacists, interns, and faculty-preceptors suggested that PMC improved their confidence, communication skills, and decision-making.&#x0D; Conclusion. The PMC service is relevant and valuable to ensure patients' rational and quality use of medicines. As a value-added service to existing hospital pharmacy services, it serves as a venue for enhancing soft skills among pharmacists and students alike. However, physical and human resources and current processes need to be upgraded to improve efficiency, ensure sustainability, and expand service coverage to more patients.</jats:p

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Abstract Adoptive cell therapy with autologous CAR-T cells has induced remarkable responses in patients with treatment-refractory hematologic malignancies, which has led to FDA approvals for two CAR-T products. However, limitations exist with commercial CAR-T centralized production: (1) off-site manufacturing can take several weeks and requires shipping from and to the treating facility; (2) off-site manufacturing limits treatment options for progressing patients; (3) high cost of the commercial products may limit their availability. To address these challenges, we used the fully automated Miltenyi CliniMACS Prodigy device, a GMP-compliant closed system, to manufacture autologous CAR-T cells for a Phase I trial (NCT03019055) evaluating a first-in-human bi-specific CAR that targets CD19 and CD20 (CD20.19 CAR). CAR-T manufacturing was performed exclusively using the CliniMACS Prodigy device and reagents obtained from Miltenyi Biotec. Production was performed within the Medical College of Wisconsin (MCW) Cell Therapy Laboratory, an ISO7 air handling environment. Manufacturing was set at 14 days, and production was as follows. First, peripheral blood mononuclear cells (MNC) were collected by apheresis, with a collection goal of 4 blood volumes to eliminate risk of a low CD3 yield in heavily pre-treated patients. Next, MNC were loaded onto the Prodigy, and CD4 and CD8 T cells enriched by positive immunomagnetic selection. To start the culture process, enriched T cells were suspended in TexMACS medium supplemented with 3% human AB serum and 200 U/mL IL-2, and TransACT reagent was added to stimulate the T cells in the Prodigy cell culture chamber. The following day (day 1), lentiviral vector expressing anti-CD19 and anti-CD20 (in tandem) with CD3ζ and 4-1BB stimulatory domains was added to the stimulated cells. Culture washes and feedings were done on days 5, 6, 8, 10 and 12 of manufacture, and final products harvested on Day 14. Protein L staining was used to detect expression of CD20.19 CAR on the T cells. On Day 14, eligible patients received fresh CAR-T cells, while for others the product was cryopreserved and administered on a later date. To date, the MCW Cell Therapy Laboratory has successfully generated CAR-T cell products for all 6 patients enrolled thus far on the Phase 1 clinical trial with no production failures (Table 1). Three patients received cryopreserved product and 3 patients received fresh product. The enriched T cells were 94.3% CD3+ (87.8-97.4%), and average T cell recovery from the apheresis cell products was 65.2% (54.2-80.0%). Protein L staining indicated 20.8% average CD20.19 CAR expression. Patient CAR-T cells were able to kill CD19+ and CD20+ target cells in vitro and produce IFN-gamma in response to the same target cells. An average yield of 5.9e+8 (4.3-7.9e+8) CAR T cells was obtained at harvest, which exceeded the required cell dose for all patients. The CAR-T cells were comprised of both CD4 and CD8 T cells, with higher expression on CD4 T cells; average CAR-T CD4:CD8 ratio on the final products was 2.8. The majority of T cells (average of 81.5%) had an effector-memory phenotype. In-process testing performed on Day 8 of manufacturing demonstrated sufficient numbers of CAR-T cells needed for patient infusions were already present, and that the CAR-T cells only expanded an additional 1.9 to 3.5-fold between Days 8 and 14. In conclusion, we have successfully demonstrated feasibility for point-of-care CAR-T cell production for clinical use from patient apheresis products utilizing the CliniMACS Prodigy device. Time to production was efficient (14 days), and patient-derived CAR-T cell products were reproducibly generated in a standard cell processing laboratory within an academic medical center. A major clinical advantage of CAR-T cells generated on-site is the flexibility in treatment. Patients can receive cells either immediately (i.e., fresh) or the cells can be cryopreserved for later infusion if the patient is not able to receive fresh cells. Based on our results, we intend to decrease the cell processing time to 10 days. Disclosures Zhu: Lentigen Technology Inc., A Miltenyi Biotec Company: Research Funding. Shah:Juno Pharmaceuticals: Honoraria; Oncosec: Equity Ownership; Geron: Equity Ownership; Exelexis: Equity Ownership; Miltenyi: Other: Travel funding, Research Funding; Lentigen Technology: Research Funding. Schneider:Lentigen Technology Inc., A Miltenyi Biotec Company: Employment. Keever-Taylor:Medical College of Wisconsin: Research Funding. Dropulic:Lentigen, A Miltenyi Biotec company: Employment. Orentas:Lentigen Technology Inc., A Miltenyi Biotec Company: Employment. Hari:Bristol-Myers Squibb: Consultancy, Research Funding; Amgen Inc.: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Honoraria; Kite Pharma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; Spectrum: Consultancy, Research Funding; Sanofi: Honoraria, Research Funding. Johnson:Miltenyi: Research Funding. </jats:sec